SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : SNRS- Sunrise Technologies -- Ignore unavailable to you. Want to Upgrade?

To: Stephen M. DeMoss who wrote (2504)6/6/1999 1:31:00 PM
From: Jay  Respond to of 4140
 
Personally, I don't think this is likely, but if you want to see what is could happen, look at the price action of ATIS (Advanced Tissue Sciences)last year. Their approval was "delayed" for further testing. The price fell from 15 to 2.

Cheers,
Jay



To: Stephen M. DeMoss who wrote (2504)6/6/1999 2:35:00 PM
From: BB BOB  Read Replies (1) | Respond to of 4140
 
Well that's the bet isn't it?? A delay would kill the options,but the stock will just be a longer hold.If this puppy ever got close to 2 bucks its mortgage time!!!That's not goin to happen,after all they are doing procedures now,so we know their close and don't forget on going discussions with the FDA...best of luck to us longs,
Regards,
Bob



To: Stephen M. DeMoss who wrote (2504)6/6/1999 10:58:00 PM
From: RockDoc  Respond to of 4140
 
Let's face it.
If the ODP rejects the PMA application we're all dead meat. But it ain't gonna happen. Why would the FDA approve fellow eye in the clinical trials? Why would they approve the current phase 3 trials for moderate hyperopia if the low hyperopia studies were flawed? Why would the presbyopia studies be approved?
Nope, the Panel will recommend approval, and the LTK technology will revolutionize the eye laser treatment industry.
JMHO
The ROCKSTER


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News